These findings may help guide the targeted therapy of cervical cancer and lead to the identification of new markers that can predict the therapeutic effect of immune checkpoint inhibitors in cervical cancer patients by integrating the expression of PD-L1, genomic variation and TMB. Here, CD274 is linked to cervical cancer.